Status:
COMPLETED
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer
Lead Sponsor:
Grupo de Investigación Clínica en Oncología Radioterapia
Conditions:
Oligometastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
This study aims to probe the effect of SBRT as a treatment oligometastases of prostate cancer, regardless of basal treatment received, and I know the response, biochemical control, the progression-fre...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed prostate cancer, who are currently being oligometastases / oligorrecurrencia after primary treatment for their disease.
- Aged ≥ 18 years
- Time to biochemical recurrence more than 1 year
- PSA doubling time\> 3 months
- Less than 5 bone metastases location (including spinal) or lymph node.
- Without other metastases or recurrences by Choline PET or / and NMR Diffusion Length.
- Signed and dated written informed consent form.
Exclusion
- Patients currently treatment with abiraterone, enzalutamide, chemotherapy, immunotherapy or radioisotopes.
- Patients unwilling or unable to comply with protocol requirements and scheduled visits.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT02192788
Start Date
August 1 2014
End Date
July 1 2021
Last Update
November 19 2021
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
GICOR
Madrid, Las Rozas, Spain, 28290
2
Hospital Puerta de Hierro
Majadahonda, Madrid, Spain
3
Hospital Rey Juan Carlos
Móstoles, Madrid, Spain
4
Santa Lucia
Cartagena, Murcia, Spain